Headache and Migraine

The director of Dysautonomia Clinic talked about the often overlooked triad of dysautonomia, hypermobility spectrum disorder, and mast cell activation syndrome in the field of headache medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders and hypersomnias.

Neurology News Network for the week ending February 24, 2024. [WATCH TIME: 3 minutes]

In a cohort of nearly 250 patients with chronic or episodic migraine, less than 2% of patients experienced adverse events while on combination treatment.

Stephen Samples, MD, provided perspective as the newly appointed chair of neurology at Allegheny Health Network, and the responsibilities that come with constructing an effective neurology department.

The director of Dysautonomia Clinic talked about the importance of focusing beyond migraine to address often overlooked comorbidities such as dysautonomia, hypermobility spectrum disorders, and mast cell activation syndrome. [WATCH TIME: 10 minutes]

Atogepant demonstrated notable efficacy in reducing monthly migraine days compared with placebo, in addition to maintaining a well-tolerated and safe profile.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Experts from different subspecialties in neurology shared their clinical perspectives for patients on promising therapeutics and expansion of care interventions for 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders, and specifically, Duchenne muscular dystrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

The observational study found no increase in migraine days at the end of treatment months for patients on erenumab or fremanezumab.

The chair of Allegheny Health Network’s department of neurology provided insight on his clinical experiences with migraine medicine and how the field needs to adapt to the ongoing changes to treatment options. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders.

A recent study showed a more than 75% reduction in migraine frequency in participants with comorbid multiple sclerosis when treated with calcitonin gene-related peptide monoclonal antibodies.

Using the validated Migraine-Related Stigma questionnaire, investigators observed significant between-group differences in disability, interictal burden, and quality of life based on the amount of migraine-related stigma experienced.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

The director of the Hartford healthcare Headache Center in Connecticut shared his and colleagues' thoughts on potential therapies that expand management care options for patients with migraine. [WATCH TIME: 7 minutes]

The dihydroergotamine product’s application was supported by phase 1 comparative pharmacokinetic and safety data, and the phase 3 ASCEND trial.